Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price fell 23.5% during trading on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. 119,000 shares were traded during mid-day trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Trading Down 23.5%
The stock has a fifty day moving average of C$0.16 and a 200 day moving average of C$0.17. The company has a market capitalization of C$19.27 million, a P/E ratio of -4.64 and a beta of 0.67. The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Featured Articles
- Five stocks we like better than Devonian Health Group
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Large Cap Stock Definition and How to Invest
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
